Last reviewed · How we verify
NCT05217524
Samsung Galaxy Watch Body Composition Study
trial testing Galaxy BIA watch in Obesity in 110 participants. Completed in 1 January 2022.
20 December 2021
Quick facts
| Lead sponsor | Pennington Biomedical Research Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 1 May 2021 |
| Primary completion | 20 December 2021 |
| Estimated completion | 1 January 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Galaxy BIA watch
Conditions studied
- Obesity — all drugs for Obesity →
- Overweight — all drugs for Overweight →
Sponsor
Pennington Biomedical Research Center — full company profile →
Who can join
18 and older, any sex, with Obesity or Overweight. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to acquire impedance measurements of the adult human body with a novel bioimpedance device housed inside a watch case and to compare derived estimates of body composition measured by dual-energy x-ray absorptiometry (DXA) and other bioimpedance analysis (BIA) systems.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Smartphone prediction of skeletal muscle mass: model development and validation in adults.
McCarthy C, Tinsley GM, Yang S, Irving BA, et al · · 2023 · cited 25× · PMID 36822238 · DOI 10.1016/j.ajcnut.2023.02.003 -
Advances in digital anthropometric body composition assessment: neural network algorithm prediction of appendicular lean mass.
Marazzato F, McCarthy C, Field RH, Nguyen H, et al · · 2024 · cited 5× · PMID 38142263 · DOI 10.1038/s41430-023-01396-3
Verify or expand the search:
- PubMed search for NCT05217524
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Pennington Biomedical Research Center trials
Trials by the same sponsor.
- NCT07530718 — Body Composition Outcomes in MS Patients · not yet recruiting
- NCT07095972 — Continuous Glucose Monitoring in Metabolic Surgery · NA · not yet recruiting
- NCT07139821 — Dietary Iron Requirements · recruiting
- NCT07318064 — Ultra-processed Food Consumption and Health Pilot Study · NA · not yet recruiting
- NCT07305753 — CanCan Body Composition Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05217524 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pennington Biomedical Research Center
- Last refreshed: 1 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05217524.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing